To investigate the cleavage of phospho-HER2, HER2 was immunoprecipitated ... trastuzumab sensitivity and pathway of survival in HER2-positive breast cancer. Activation of calpain regulates at ...

Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, ...

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

BT474 BT474Res SKBR3 SKBR3Res Trastuzumab (10 nM) 53.3 ± 4.9 90.4 ± 7.6 69.5 ± 16.1 79.5 ± 8.2 AUY922 (10 nM) 55.0 ± 1.1 92.6 ± 11.9 33.3 ± 9.7 19.1 ± 6.1 Trastuzumab+AUY922 22.0 ± 2.3 59.7 ± 17.5 ...

HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 ...

Learn about HER2-positive breast cancer, its symptoms, causes, and prevention tips. Understand early signs and available ...

Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death.

But having treated breast cancer and seeing the drug development, I think people with Her2-positive breast cancer should be encouraged to know that we have drugs that increase the cure rate ...

Enhertu showed significant improvement in pathologic complete response rates in high-risk HER2-positive early-stage breast cancer compared with standard care. The DESTINY-Breast11 trial indicated ...

Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, Kadcyla), according to long-term follow-up of a large clinical trial.